New York, July 13, 2026 — Pfizer (NYSE:PFE) shares climbed 1.28% to $24.48 in post-market trading Monday, bucking a broad market decline driven by rising U.S.-Iran tensions, higher oil prices, and a sharp selloff in semiconductor stocks. The pharmaceutical giant significantly outperformed the S&P 500, which fell 0.79%, and the Nasdaq Composite, which dropped 1.55%. Among its peers, Pfizer also outpaced Merck (MRK), up 0.40%, and Johnson & Johnson (JNJ), up 0.34%.
The defensive move comes as investors seek shelter from risk-on assets, with Pfizer's attractive dividend yield of approximately 7.0% providing a compelling income stream. The company maintains a quarterly dividend of $0.43 per share, annualizing to $1.72, which is supported by its 2026 adjusted earnings per share guidance of $2.80 to $3.00. This payout ratio of 57%-61% of earnings leaves room for sustainability, though first-quarter cash dividends of $2.4 billion consumed about 89% of net income.
Options Market Shows Caution
Despite the stock's positive move, options traders exhibited a more guarded stance. Around 128,000 contracts changed hands, with the put/call ratio rising to 0.81, 37% above the typical 0.59 level. This indicates increased demand for downside protection, even as the overall tilt remained moderately bullish. Implied volatility priced in a daily move of $0.36, or 1.5% of the share price, suggesting the market expects continued choppiness.
This cautious sentiment contrasts with the previous week, when Pfizer fell 2.47% on July 6 while the S&P 500 rose 0.72%. Since then, Pfizer has gained about 3.2% relative to the index, marking a shift toward income-oriented stocks rather than a change in long-term profit expectations for the company.
Padcev Approval Bolsters Pipeline
The recent U.S. approval of Padcev, developed jointly with Astellas Pharma (TYO:4503), stands as a key growth catalyst. The drug, used in combination with Merck's Keytruda, is now cleared for pre- and post-surgery treatment in muscle-invasive bladder cancer. A Phase 3 trial showed the combination reduced the risk of recurrence, progression, or death by 47%, and lowered the risk of death by 35%. After two years, 79.4% of patients on the regimen were event-free, compared to 66.2% for chemotherapy.
Padcev is already one of Pfizer's faster-growing drugs, with first-quarter sales rising 39% operationally. This helped offset declining COVID-product revenue, as launched and acquired medicines climbed 22% in the quarter. JPMorgan analyst Chris Schott noted that the pipeline "could make the story more interesting over time," but cautioned that investors still seek more clinical data and less development risk.
Wall Street Sentiment Mixed
Analyst views remain divided. Bank of Montreal's BMO Capital Markets lowered its price target to $30 from $34 but maintained an Outperform rating, while Guggenheim trimmed its target to $35 from $36 with a Buy. Both imply upside of 23% and 43%, respectively, from Monday's close. However, BMO warned that the sentiment rebound may fade without strong second-quarter commercial results.
On the bearish side, HSBC analyst Rajesh Kumar downgraded the stock to Hold, citing a "paucity of short-term re-rating catalysts" and assigning only a 40% probability that sigvotatug vedotin, a failed lung cancer drug, reaches the market. Higher adverse event rates for Padcev (75.7% serious or severe events vs. 67.2% for chemo) could also slow physician adoption.
Key Dates Ahead
August 4 is the next critical date, when Pfizer reports second-quarter earnings. Investors will scrutinize Padcev sales momentum, whether earnings cover the dividend, and whether full-year guidance remains intact. For now, Pfizer offers a high-yield defensive play in a volatile market, but options activity suggests the market remains unconvinced this is a sustainable shift back to growth.
